Date: 2017-05-12
Type of information: Capital increase
Company: Theradiag (France)
Investors:
Amount: €4 million
Funding type: capital increase
Planned used:
- The funds raised will enable Theradiag to facilitate and step up its international development and the marketing of its auto-immunity, allergy and theranostics products.
Others:
- • On May 12, 2017, Theradiag announced that the company has successfully completed a capital increase by issuing shares to a specific category of persons following an accelerated bookbuilding process. The company has sold 1,749,563 new shares with par value of €1.70 each, at a price of €2.30 each including the issue premium, for a total amount of €4,023,994.90 and representing 20.21% of the company’s post-transaction capital. For reference, the interest of a shareholder owning 1% of the company’s share capital before the issue will be reduced to 0.8% after the issue.
- The transaction was carried out following decisions by the Board of Directors and CEO on May 11, 2017, in accordance with the authority granted by the 15th resolution approved by the Combined General Meeting of Shareholders of April 27, 2017. The issue price represented a discount of 15.6% to the volume-weighted average price in the five trading sessions before the Board’s decision.
- The capital increase took place through the issue of ordinary shares without preferential subscription rights to a specific category of persons. Settlement of the shares newly issued as part of the capital increase and their admission to Euronext Paris’ Alternext Paris market are expected to take place on May 17, 2017. The new shares will rank for dividends immediately and will be admitted to trading on Alternext Paris under ISIN code FR0004197747 – ALTER. Theradiag’s share capital will be made up of 8,654,944 shares after settlement has taken place.
- Post-capital increase and disposal of shares by investment funds managed by Truffle Capital, the ownership structure of the Company’s shares significantly changed. Post-transaction, HOB Capital holds 8.56% of the total capital and the free float is 91.44%. EuroLand Corporate has advised Theradiag.
Therapeutic area: Diagnostic - Autoimmune diseases - Immunological diseases
Is general: Yes
